Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 13:12:669638.
doi: 10.3389/fphar.2021.669638. eCollection 2021.

Natural Compounds as Medical Strategies in the Prevention and Treatment of Psychiatric Disorders Seen in Neurological Diseases

Affiliations
Review

Natural Compounds as Medical Strategies in the Prevention and Treatment of Psychiatric Disorders Seen in Neurological Diseases

Esra Küpeli Akkol et al. Front Pharmacol. .

Abstract

Psychiatric disorders are frequently encountered in many neurological disorders, such as Alzheimer's and Parkinson diseases along with epilepsy, migraine, essential tremors, and stroke. The most common comorbid diagnoses in neurological diseases are depression and anxiety disorders along with cognitive impairment. Whether the underlying reason is due to common neurochemical mechanisms or loss of previous functioning level, comorbidities are often overlooked. Various treatment options are available, such as pharmacological treatments, cognitive-behavioral therapy, somatic interventions, or electroconvulsive therapy. However oral antidepressant therapy may have some disadvantages, such as interaction with other medications, low tolerability due to side effects, and low efficiency. Natural compounds of plant origin are extensively researched to find a better and safer alternative treatment. Experimental studies have shown that phytochemicals such as alkaloids, terpenes, flavonoids, phenolic acids as well as lipids have significant potential in in vitro and in vivo models of psychiatric disorders. In this review, various efficacy of natural products in in vitro and in vivo studies on neuroprotective and their roles in psychiatric disorders are examined and their neuro-therapeutic potentials are shed light.

Keywords: Alzheimer's diseases; Parkinson's disease; anxiety; depression; natural compound.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The Associate Editor A.O.D declared a past collaboration with Authors R.C and E.S-S.

Figures

FIGURE 1
FIGURE 1
Mechanism involve in development of neurodegenerative disorders.
FIGURE 2
FIGURE 2
Symptom overlap between anxiety and depression.
FIGURE 3
FIGURE 3
The modulation of neuronal survival and death protein kinase pathways via flavonoids, phenolic acids, and terpenes. The activation of ERK1/2, PI3K/Akt, and PKC pathways act to stimulate neuronal survival through the induction of pro-survival or antiapoptotic genes and by inhibition of pro-apoptotic proteins. JNK1/2 and p38 are stress-activated pathways and cause neuronal death. Furthermore, the inhibitory actions of flavonoids, phenolic acids, and terpenes in the JNK1/2 and p38 pathways are possible to be neuroprotective in the occurrence of stress signals. Though, flavonoids, phenolic acids, and terpenes have neuromodulatory and neuroprotective assets and prevent neuronal function by stimulatory and inhibitory actions at these signaling pathways.

Similar articles

Cited by

References

    1. Aarsland D., Påhlhagen S., Ballard C. G., Ehrt U., Svenningsson P. (2012). Depression in Parkinson Disease-Epidemiology, Mechanisms and Management. Nat. Rev. Neurol. 8 (1), 35–47. 10.1038/nrneurol.2011.189 - DOI - PubMed
    1. Adams J., Wang R., Yang J., Lien E. (2006). Preclinical and Clinical Examinations of Salvia Miltiorrhiza and its Tanshinones in Ischemic Conditions. Chin. Med. 1 (3), 3. 10.1186/1749-8546-1-3 - DOI - PMC - PubMed
    1. Adibhatla R. M., Hatcher J. F. (2017). Role of Lipids in Brain Injury and Diseases. Future Lipidol. 2 (4), 403–422. 10.2217/17460875.2.4.403 - DOI - PMC - PubMed
    1. Akbar S., Subhan F., Karim N., Aman U., Ullah S., Shahid M., et al. (2017). Characterization of 6-methoxyflavanone as a Novel Anxiolytic Agent: A Behavioral and Pharmacokinetic Approach. Eur. J. Pharmacol. 801, 19–27. 10.1016/j.ejphar.2017.02.047 - DOI - PubMed
    1. Al Mansouri S., Ojha S., Al Maamari E., Al Ameri M., Nurulain S. M., Bahi A. (2014). The Cannabinoid Receptor 2 Agonist, β-caryophyllene, Reduced Voluntary Alcohol Intake and Attenuated Ethanol-Induced Place Preference and Sensitivity in Mice. Pharmacol. Biochem. Behav. 124, 260–268. 10.1016/j.pbb.2014.06.025 - DOI - PubMed

LinkOut - more resources